登录新浪财经APP 搜索【信披】查看更多考评等级 一、本次投资概述 上海泰坦科技股份有限公司（以下简称"公司"）于2025年9月25日披露《关于认购创业投资基金份额的 公告》（公告编号：2025-041），公司拟作为有限合伙人以自有资金2,900万元人民币认购上海泰礼璟 源创业投资合伙企业（有限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海泰礼璟源创业投资合伙企业（有限合伙） 上海泰坦科技股份有限公司董事会 公司将密切关注合伙企业后续经营管理状况，敦促其加强投资管理及风险控制，切实降低投资风险，并 严格按照信息披露管理相关规定及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 根据《上海证券交易所科创板股票上市规则》《上海泰坦科技股份有限公司章程》及《对外投资管理制 度》等相关规定，本次对外投资已经公司总经理批准，无需提交公司董事会及股东大会审议。本次投资 不属于关联交易，亦不 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-048 接力基金第七期首关认缴出资为 24,200 万元，其中公司拟作为有限合伙人以 自有资金出资人民币 2,900 万元认购接力基金第七期 11.9835%的财产份额。待基 金完成最终募集后，基金总认缴出资额不超过 40,000 万元，其中泰坦科技认缴出 资额保持 2900 万元。合伙企业的出资额、合伙人名册及出资比例等信息以工商登 记为准。 上述投资具体内容详见公告。 二、进展情况介绍 上海泰坦科技股份有限公司 关于对外投资进展暨完成工商登记的公告 一、本次投资概述 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日披露 《关于认购创业投资基金份额的公告》（公告编号：2025-041），公司拟作为有 限合伙人以自有资金 2,900 万元人民币认购上海泰礼璟源创业投资合伙企业（有 限合伙）（以下简称"接力基金第七期"或"合伙企业"）份额。 根据《上海证券交易所科创板股票上市规则》《上 ...

泰坦科技公告，公司作为有限合伙人以自有资金2900万元人民币认购上海泰礼璟源创业投资合伙企业 （有限合伙）份额。接力基金第七期首关认缴出资为2.42亿元，泰坦科技认购11.9835%的财产份额。待 基金完成最终募集后，基金总认缴出资额不超过4亿元，泰坦科技认缴出资额保持2900万元。合伙企业 已完成工商注册登记，出资额为2.42亿元人民币，成立日期为2025年12月15日。 ...

Core Insights - Titan Technology is emerging as a key player in the domestic scientific services industry, breaking free from overseas technology monopolies and weak industrial foundations [1][6] - The company aims to enhance technological self-reliance and improve the overall efficiency of the innovation system during the 14th Five-Year Plan period [1][6] - Titan Technology has established a comprehensive manufacturing system covering three core categories: reagents, consumables, and instruments [2][5] Company Development - Titan Technology has evolved from a startup in 2007 to the first stock in the scientific services sector listed on the STAR Market in 2020 [1][6] - The company has built a full industrial chain manufacturing system and is expanding its production capacity with new bases in Shanghai, Hubei, and Anhui [2][5] - The Shanghai Songjiang base has achieved breakeven, while the Anhui base leads in ultra-pure solvent production in Asia [2][5] R&D and Innovation - In the first half of 2025, Titan Technology's R&D investment reached 80.36 million yuan, resulting in new products and 27 patents [2][5] - The company is focused on upgrading its manufacturing capabilities to meet high-end market demands, transitioning from "making bicycles" to "making airplanes" [2][5] Mergers and Acquisitions - Titan Technology has utilized mergers and acquisitions as a strategy to enhance its product capabilities, including the acquisition of Apollo Scientific Ltd. for approximately £5.75 million [5][6] - The company has successfully integrated acquired firms, leading to revenue growth in the first half of 2024 [5][6] Future Outlook - Titan Technology plans to enter a critical phase of results validation in the next 3 to 5 years, following significant investments in its production bases [3][7] - The company aims to compete globally by establishing a diversified brand matrix and leveraging its extensive customer base, which includes over 60,000 clients and more than 150 Fortune 500 companies [6][7]

Group 1 - Shanghai's "14th Five-Year Plan" outlines a strategic blueprint for high-quality development, emphasizing innovation and internationalization for local tech companies [1][2] - Companies like Titan Technology, Kasei Biotech, and Yingfang Software are leveraging Shanghai's supportive ecosystem to tackle key technological challenges and expand into global markets [1][2][19] - Kasei Biotech aims to become a pioneer in the global biomanufacturing industry, focusing on high-value utilization of biomass and synthetic biology technologies [4][11][12] Group 2 - Titan Technology has transitioned from a focus on basic manufacturing to a comprehensive production system covering reagents, consumables, and instruments, with significant investments in capacity expansion [19][20][21] - The company has established a full industrial chain and is actively pursuing mergers and acquisitions to enhance its product capabilities and market presence [22][23] - Titan Technology's goal during the "14th Five-Year Plan" is to break into the global market, supported by a strong customer base and ongoing product development [24][25] Group 3 - Yingfang Software has developed a robust disaster recovery system, addressing critical data management needs for various industries, including finance and healthcare [13][14][15] - The company has achieved significant market penetration, serving over 6,000 clients globally, and aims to increase its international revenue share [13][18] - Yingfang Software is focusing on AI integration and international expansion to enhance its competitive edge in the data resilience sector [17][18] Group 4 - Chuangyuan Xinke is advancing communication testing technologies, with a focus on 6G and satellite communication, and has invested heavily in R&D to maintain its competitive position [27][28][29] - The company is expanding its testing capabilities to cover low-altitude and satellite communication, aiming to provide comprehensive testing solutions across various domains [29][30] - Chuangyuan Xinke is also exploring opportunities in the robotics testing sector, recognizing its potential for long-term growth [34][35]

证券代码：688133 证券简称：泰坦科技 公告编号：2025-047 上海泰坦科技股份有限公司 关于董事离任暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海泰坦科技股份有限公司（以下简称"公司"）董事会于近日收到董 事定高翔先生的书面辞职报告。因公司治理结构调整及工作安排调整原因，定高 翔先生申请辞去董事职务，根据《中华人民共和国公司法》（以下简称"《公司 法》"）和《公司章程》的有关规定，定高翔先生的辞职报告自送达公司董事会 时生效。 2025 年 12 月 5 日，公司召开职工代表大会，选举顾梁先生担任公司第 四届董事会职工董事，任期自职工代表大会选举之日起至第四届董事会任期届满 之日止。 (二) 离任对公司的影响 定高翔先生的离任不会导致公司董事会人数低于法定人数，不会影响公司董 事会的正常运作，不会对公司日常生产经营等产生不利影响。其不存在未履行完 毕的公开承诺。 二、职工董事选举情况 根据《中华人民共和国公司法》《上市公司章程指引》等法律法规和规范性 文件及《公司章程》的相 ...

Summary of Conference Call Records Industry Overview - The medical device industry is experiencing overall performance pressure in 2025, but third-quarter revenues have shown a year-on-year increase, with a narrowing decline in net profit attributable to the parent company, primarily due to domestic medical insurance cost control and geopolitical influences. It is expected that normal growth rates will resume in 2026 [1][3][8]. Key Points on Medical Device Sector - **Domestic Market Dynamics**: The slowdown in hospital bidding in 2024 is impacting revenue realization, with an expected boost from the "old-for-new" policy by the end of 2025. The In Vitro Diagnostics (IVD) sector is under pressure due to centralized procurement price adjustments and tax reimbursements [1][4]. - **International Market Challenges**: Companies are strengthening their overseas presence, but initial high costs are pressuring short-term profits. The impact of US-China tariffs on low-value consumables is significant, with expectations of price recovery in the glove industry from late 2025 to 2026 after inventory digestion [1][4][11]. - **Performance Metrics**: In the first three quarters of 2025, the medical device sector reported revenues of 145.7 billion yuan, a year-on-year decline of 2.4%, and a net profit of 26.5 billion yuan, down 14.4%. However, the third quarter showed a positive revenue trend and a narrowing profit decline [3][15]. Specific Sector Insights - **IVD Sector**: The IVD sector saw a year-on-year decline of 14.5% in the first three quarters, but the third quarter showed improvement with revenues of 11.02 billion yuan, benefiting from the implementation of centralized procurement and the release of DRG/DIP 2.0 [16]. - **High-Value Consumables**: This segment experienced a revenue growth of 6.6% year-on-year, with orthopedics showing a significant growth rate of 18.7%. The recovery in cardiovascular surgeries is driving sales, and the ophthalmology sector presents potential due to low penetration rates [17]. - **Medical Equipment**: The medical equipment sector's revenue remained flat, but profit growth was slightly higher. The imaging equipment sector is benefiting from the "old-for-new" projects, with a notable recovery in the endoscope segment [15]. Vaccine Sector Performance - The vaccine sector faced significant pressure, with revenues declining nearly 50% and profits turning negative. However, there is a quarter-on-quarter improvement trend. Future focus includes the recovery of traditional vaccines and the launch of new pipeline products, such as the domestically produced nine-valent HPV vaccine [2][23]. Life Sciences Upstream Sector - The life sciences upstream sector's performance remained stable, with a year-on-year profit growth of 68% in the third quarter, driven by recovering terminal demand and improved gross margins. The sector is benefiting from the expansion of the biopharmaceutical market and policy support [24]. Regulatory Environment and Challenges - The current regulatory environment emphasizes innovation while ensuring safety and efficacy. Domestic companies face challenges in international certifications, particularly with the FDA and CE, due to quality control issues [20][21][22]. Future Outlook - The industry outlook for 2026 includes a focus on self-sufficiency, innovative devices, and accelerated realization of centralized procurement categories. The recovery of orthopedic products is already evident, and international expansion remains a key area of interest [5][7][19].

Core Viewpoint - Titan Technology's stock has experienced fluctuations, with a year-to-date increase of 23.83% but a recent decline over the past 20 and 60 days, indicating potential volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Titan Technology reported a revenue of 1.848 billion yuan, representing a year-on-year decrease of 13.06%. However, the net profit attributable to shareholders increased by 15.04% to 11.1678 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, Titan Technology had 9,293 shareholders, an increase of 20.41% from the previous period. The average number of circulating shares per shareholder decreased by 16.95% to 17,694 shares [2]. Business Overview - Titan Technology, established on October 18, 2007, and listed on October 30, 2020, is based in Shanghai and specializes in providing integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals. The main revenue sources are research reagents (42.70%), research instruments and consumables (28.42%), and specialized chemicals (26.48%) [1].

Core Viewpoint - Shanghai Titan Technology Co., Ltd. has announced a change in its main office address to enhance internal management and facilitate communication with investors [1] Company Contact Information Changes - The company has updated its main office address while other contact methods, such as the investor hotline, remain unchanged [1] - The new contact address is: No. 258, Lane 3111, Huancheng West Road, Fengxian District, Shanghai, Postal Code: 201402 [1] - The company's website is https://www.titansci.com/ and the investor email is contact@titansci.com [1] - The investor hotline is 021-60878330 and the fax number is 021-60878355 [1]

（文章来源：证券日报） 证券日报网讯 12月1日晚间，泰坦科技发布公告称，因内部管理需要，公司于近日对主要办公地址进行 了调整，变更后主要办公地址为上海市奉贤区环城西路3111弄258号，邮政编码201402。 ...